Literature DB >> 9569035

Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours.

Z Sedlacek1, R Kodet, V Kriz, E Seemanova, P Vodvarka, P Wilgenbus, J Mares, A Poustka, P Goetz.   

Abstract

We describe two Li-Fraumeni syndrome families. Family A was remarkable for two early childhood cases of adrenocortical tumours, family B for a high incidence of many characteristic cancers, including a childhood case of choroid plexus tumour. Using direct sequencing, we analysed exons 5-9 of the p53 gene in constitutional DNA of individuals from both families and found two novel germline mutations in exon 5. In family A, we detected a point substitution in codon 138 (GCC to CCC), which resulted in the replacement of the alanine by a proline residue. Family B harboured a single-base pair deletion in codon 178 (CAC to -AC), resulting in a frameshift and premature chain termination. Three out of six tumours examined from both families, a renal cell carcinoma, a rhabdomyosarcoma and a breast cancer, showed loss of heterozygosity and contained only the mutant p53 allele. The remaining three neoplasms, both adrenocortical tumours and the choroid plexus tumour retained heterozygosity. Immunohistochemistry with anti-p53 antibody confirmed accumulation of p53 protein in tumours with loss of heterozygosity, while the remaining tumours were p53 negative. These results support the view that complete loss of activity of the wild-type p53 need not be the initial event in the formation of all tumours in Li-Fraumeni individuals.

Entities:  

Mesh:

Year:  1998        PMID: 9569035      PMCID: PMC2150131          DOI: 10.1038/bjc.1998.172

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene.

Authors:  J M Varley; M Thorncroft; G McGown; J Appleby; A M Kelsey; K J Tricker; D G Evans; J M Birch
Journal:  Oncogene       Date:  1997-02-20       Impact factor: 9.867

2.  Point mutation analysis in a mammalian gene: rapid preparation of total RNA, PCR amplification of cDNA, and Taq sequencing by a novel method.

Authors:  A M Carothers; G Urlaub; J Mucha; D Grunberger; L A Chasin
Journal:  Biotechniques       Date:  1989-05       Impact factor: 1.993

3.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Authors:  F P Li; J F Fraumeni
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

Review 4.  Germline mutations in the TP53 gene.

Authors:  R A Eeles
Journal:  Cancer Surv       Date:  1995

5.  Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.

Authors:  J Toguchida; T Yamaguchi; S H Dayton; R L Beauchamp; G E Herrera; K Ishizaki; T Yamamuro; P A Meyers; J B Little; M S Sasaki
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

6.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.

Authors:  S Srivastava; Z Q Zou; K Pirollo; W Blattner; E H Chang
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

7.  Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors.

Authors:  L M Weiss
Journal:  Am J Surg Pathol       Date:  1984-03       Impact factor: 6.394

8.  Unusual scarcity of restriction site polymorphism in the human thyroglobulin gene. A linkage study suggesting autosomal dominance of a defective thyroglobulin allele.

Authors:  F Baas; H Bikker; G J van Ommen; J J de Vijlder
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

9.  A cancer family syndrome in twenty-four kindreds.

Authors:  F P Li; J F Fraumeni; J J Mulvihill; W A Blattner; M G Dreyfus; M A Tucker; R W Miller
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

10.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

View more
  7 in total

1.  TP53 gene mutations are rare in nondysplastic Barrett's esophagus.

Authors:  Kamila Novotna; Marie Trkova; Alexandr Pazdro; Milan Smejkal; Alzbeta Soukupova; Daniela Kodetova; Premysl Smejkal; Zdenek Sedlacek
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

2.  Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation.

Authors:  Mariëlle W G Ruijs; Senno Verhoef; Gea Wigbout; Roelof Pruntel; Arno N Floore; Daphne de Jong; Laura J van T Veer; Fred H Menko
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

3.  Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors.

Authors:  J M Varley; G McGown; M Thorncroft; L A James; G P Margison; G Forster; D G Evans; M Harris; A M Kelsey; J M Birch
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

4.  The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.

Authors:  M Babjuk; V Soukup; J Mares; J Dusková; Z Sedlácek; M Trková; L Pecen; J Dvorácek; T Hanus; R Kocvara; J Novák; C Povýsil
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

5.  Regional analysis of p53 mutations in rheumatoid arthritis synovium.

Authors:  Yuji Yamanishi; David L Boyle; Sanna Rosengren; Douglas R Green; Nathan J Zvaifler; Gary S Firestein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

6.  Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity.

Authors:  L van der Weyden; A G Rust; R E McIntyre; C D Robles-Espinoza; M del Castillo Velasco-Herrera; R Strogantsev; A C Ferguson-Smith; S McCarthy; T M Keane; M J Arends; D J Adams
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

7.  Investigations on a clinically and functionally unusual and novel germline p53 mutation.

Authors:  J Rutherford; C E Chu; P M Duddy; R S Charlton; P Chumas; G R Taylor; X Lu; D M Barnes; R S Camplejohn
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.